Terms: = Liver cancer AND CTNNB1, P35222, 1499, ENSG00000168036, CTNNB AND Prognosis
81 results:
1. Identification of molecular characteristics of hepatocellular carcinoma with microvascular invasion based on deep targeted sequencing.
Zheng L; Wang Y; Liu Z; Wang Z; Tao C; Wu A; Li H; Xiao T; Li Z; Rong W
Cancer Med; 2024 Apr; 13(7):e7043. PubMed ID: 38572921
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic and predictive biomarkers in paediatric solid tumours.
Glembocki AI; Somers GR
Pathology; 2024 Mar; 56(2):283-296. PubMed ID: 38216399
[TBL] [Abstract] [Full Text] [Related]
3. Tumor biology, immune infiltration and liver function define seven hepatocellular carcinoma subtypes linked to distinct drivers, survival and drug response.
Wu R; Gao Y; Zhao X; Guo S; Zhou H; Zhang Y; Hou Y; Mei L; Zhi H; Wang P; Li X; Ning S; Zhang Y
Comput Biol Med; 2023 Dec; 167():107593. PubMed ID: 37883849
[TBL] [Abstract] [Full Text] [Related]
4. Role of immune related genes in predicting prognosis and immune response in patients with hepatocellular carcinoma.
Chen Y; Shen C; Wu J; Yan X; Huang Q
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23519. PubMed ID: 37665680
[TBL] [Abstract] [Full Text] [Related]
5. Integrated exome sequencing and microarray analyses detected genetic defects and underlying pathways of hepatocellular carcinoma.
Chong ML; Knight J; Peng G; Ji W; Chai H; Lu Y; Wu S; Li P; Hu Q
Cancer Genet; 2023 Aug; 276-277():30-35. PubMed ID: 37418972
[TBL] [Abstract] [Full Text] [Related]
6. Hepatocellular Adenoma: Report of 2 Cases That Highlight the Relevance of Phenotype-Genotype Correlation in the Pediatric Population.
Jiao J; Finberg KE; Jain D; Morotti R
Pediatr Dev Pathol; 2023; 26(4):394-403. PubMed ID: 37334553
[TBL] [Abstract] [Full Text] [Related]
7. An immune-related biomarker index for predicting the effectiveness of immunotherapy and prognosis in hepatocellular carcinoma.
Wu X; Jin B; Liu X; Mao Y; Wan X; Du S
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10319-10333. PubMed ID: 37273105
[TBL] [Abstract] [Full Text] [Related]
8. Construction of a lipid metabolism-related risk model for hepatocellular carcinoma by single cell and machine learning analysis.
Mou L; Pu Z; Luo Y; Quan R; So Y; Jiang H
Front Immunol; 2023; 14():1036562. PubMed ID: 36936948
[TBL] [Abstract] [Full Text] [Related]
9. Can MRI features predict clinically relevant hepatocellular carcinoma genetic subtypes?
Liu X; Guo Y; Zhao L; Misdraji J; Kapur T; Abrams TA; Shyn PB
Abdom Radiol (NY); 2023 Jun; 48(6):1955-1964. PubMed ID: 36933025
[TBL] [Abstract] [Full Text] [Related]
10. Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma.
Yan ZJ; Yu CT; Chen L; Wang HY
Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36882021
[TBL] [Abstract] [Full Text] [Related]
11. [Differential diagnostic between hepatocellular carcinoma and hepatoid carcinoma with bone metastasis revelation: What tools can be used?].
Neyrand S; Bringuier PP; Benzerdjeb N; Hervieu V; Fenouil T
Ann Pathol; 2023 Sep; 43(5):407-411. PubMed ID: 36822899
[TBL] [Abstract] [Full Text] [Related]
12. Genomic landscape of Chinese patients with hepatocellular carcinoma using next-generation sequencing and its association with the prognosis.
Yang Z; Liu J; Xue F; Zhang L; Xue H; Wu Y; Bai S; Du F; Wang X; Deng W; Song C; Wang K
Ann Hepatol; 2023; 28(2):100898. PubMed ID: 36634747
[TBL] [Abstract] [Full Text] [Related]
13. State of the art and perspectives in pediatric hepatocellular carcinoma.
Digiacomo G; Serra RP; Turrini E; Tiri A; Cavazzoni A; Alfieri R; Bertolini P
Biochem Pharmacol; 2023 Jan; 207():115373. PubMed ID: 36513143
[TBL] [Abstract] [Full Text] [Related]
14. Custom gene expression panel for evaluation of potential molecular markers in hepatocellular carcinoma.
Pallerla SR; Hoan NX; Rachakonda S; Meyer CG; Van Tong H; Toan NL; Linh LTK; Giang DP; Kremsner PG; Bang MH; Song LH; Velavan TP
BMC Med Genomics; 2022 Nov; 15(1):235. PubMed ID: 36345011
[TBL] [Abstract] [Full Text] [Related]
15. Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets.
Fujita M; Chen MM; Siwak DR; Sasagawa S; Oosawa-Tatsuguchi A; Arihiro K; Ono A; Miura R; Maejima K; Aikata H; Ueno M; Hayami S; Yamaue H; Chayama K; Lee JS; Lu Y; Mills GB; Liang H; Nishizuka SS; Nakagawa H
Nat Commun; 2022 Oct; 13(1):6481. PubMed ID: 36309506
[TBL] [Abstract] [Full Text] [Related]
16. Overview and clinical significance of multiple mutations in individual genes in hepatocellular carcinoma.
Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Otsuka S; Ohnami S; Nagashima T; Hatakeyama K; Sugino T; Urakami K; Akiyama Y; Yamaguchi K
BMC Cancer; 2022 Oct; 22(1):1046. PubMed ID: 36199046
[TBL] [Abstract] [Full Text] [Related]
17. Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
Hong T; Su W; Pan Y; Tian C; Lei G
Front Immunol; 2022; 13():951459. PubMed ID: 36189258
[TBL] [Abstract] [Full Text] [Related]
18. Mutational and transcriptional alterations and clinicopathological factors predict the prognosis of stage I hepatocellular carcinoma : Prediction of stage I HCC prognosis.
Li Z; Gao H; Zhang X; Liu Q; Chen G
BMC Gastroenterol; 2022 Sep; 22(1):427. PubMed ID: 36153509
[TBL] [Abstract] [Full Text] [Related]
19. Four-copy number alteration (CNA)-related lncRNA prognostic signature for liver cancer.
Cheng Z; Guo Y; Sun J; Zheng L
Sci Rep; 2022 Aug; 12(1):14261. PubMed ID: 35995822
[TBL] [Abstract] [Full Text] [Related]
20. Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas.
Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Yamamoto Y; Ashida R; Ohgi K; Nagashima T; Yamaguchi K
J Hepatobiliary Pancreat Sci; 2023 Mar; 30(3):269-282. PubMed ID: 35918906
[TBL] [Abstract] [Full Text] [Related]
[Next]
